The U.S. President has issued an amendment to the February 1, 2025, Executive Order on import duties related to China’s synthetic opioid supply chain. The updated order modifies de minimis treatment under 19 U.S.C. 1321, allowing eligible covered articles to continue receiving duty-free entry—but only temporarily.
Under the amendment, this exemption will be revoked once the Secretary of Commerce notifies the President that adequate systems are in place to efficiently process and collect the required tariff revenue. This means businesses importing previously exempt goods from China should prepare for potential new tariffs in the future.
For more information, please visit: Executive Order Amendment Details